Roche Palo Alto LLC

Maria Elena Fuentes

Paul Parren

Stefan Seeber

Jan Van De Winkel

Ralf Schumacher

Yvo Graus

Frank Rebers

Martine Van Vugt

Aran Frank Labrijn

Elsie M Eugui

Martin Lanzendoerfer

Joseph Endl

Joerg Thomas Regula

Kay-Gunnar Stubenrauch

Adelbert Grossmann

Josef Endl

Jan Olaf Stracke

Sebastian Neumann

Sandra Vereecken-Verploegen

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

Anti-OX40L antibodies

The instant specification discloses an antibody binding to IL-13R&#x3b1;1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.

Antibodies against IL-13 receptor alpha1 and uses thereof

Growing community of inventors

Sunnyvale, CA, United States of America

Maria Elena Fuentes